v3.20.2
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2020
Sep. 30, 2019
Sep. 30, 2020
Sep. 30, 2019
COSTS AND EXPENSES:        
Research and development $ 2,683,944 $ 2,703,831 $ 7,765,673 $ 6,821,775
General and administrative 1,225,993 1,260,048 3,725,153 3,972,275
Total costs and expenses 3,909,937 3,963,879 11,490,826 10,794,050
LOSS FROM OPERATIONS (3,909,937) (3,963,879) (11,490,826) (10,794,050)
OTHER INCOME (EXPENSE):        
Gain on revaluation of derivative warrants   46,000   43,000
Interest income, net 374 14,072 11,730 38,041
Total other income, net 374 60,072 11,730 81,041
NET LOSS $ (3,909,563) $ (3,903,807) $ (11,479,096) $ (10,713,009)
BASIC AND DILUTED NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS PER COMMON SHARE $ (0.15) $ (0.42) $ (0.69) $ (1.51)
SHARES USED IN COMPUTING BASIC AND DILUTED NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS PER COMMON SHARE 26,326,782 9,386,703 16,539,183 7,098,285

Source